Long non-coding RNA XIST as a potential prognostic biomarker in human cancers: a meta-analysis

Shaopu Hu, Junli Chang, Yimian Li, Wenyi Wang, Mengyao Guo, Edward C. Zou, Yongjun Wang and Yanping Yang _

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:13911-13919. https://doi.org/10.18632/oncotarget.23744

Metrics: PDF 1679 views  |   HTML 1627 views  |   ?  


Shaopu Hu1,3, Junli Chang1,3, Yimian Li1,3, Wenyi Wang1,3, Mengyao Guo1,3, Edward C. Zou4, Yongjun Wang1,2,3 and Yanping Yang1,3

1Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, 200032, China

2School of Rehabilitation Science, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China

3Key Laboratory of Theory and Therapy Of Muscles And Bones, Ministry of Education, Shanghai, 200032, China

4Consulting Engagement Management, Cerner, Kansas City, MO, 64117, USA

Correspondence to:

Yanping Yang, email: [email protected]

Keywords: lncRNA; XIST; human cancer; meta-analysis; prognostic biomarker

Received: September 07, 2017     Accepted: November 13, 2017     Published: December 26, 2017


Growing studies have confirmed that long non-coding RNAs (lncRNAs) involve in the occurrence and development of various cancers. XIST, as a lncRNA, was dysregulated in different cancers. This meta-analysis was performed to evaluate the prognostic potential of XIST in malignant tumors. Eight databases of PubMed, Web of Science, Embase, Cochrane library, CNKI, VIP, SinoMed and Wang Fang were comprehensively searched from their initiation date to August 15, 2017. A total of nine studies with 853 cancer patients met the including criteria were finally included in this meta-analysis after independently screening the literatures by two researchers. Any discrepancies were resolved by a consensus. Hazard ratios (HRs) with corresponding 95% confidence intervals (CIs) for the primary endpoints were extracted and pooled for meta-analysis. Our results showed that expression level of XIST was markedly associated with overall survival (function as oncogene, HR = 0.53, 95% CI: 0.42–0.68, p < 0.00001; function as tumor suppressor, HR = 2.25, 95% CI: 1.15–4.37, p = 0.02), disease free survival (DFS)(HR = 0.45; 95% CI: 0.31–0.67, p < 0.0001), tumor type (digestive system carcinoma, HR = 0.50; 95% CI: 0.37–0.69, p < 0.00001; non-digestive system carcinoma, HR = 0.58; 95% CI: 0.39–0.87, p = 0.008), lymph node metastasis (OR = 0.32, 95% CI: 0.20–0.52, p < 0.00001), distant metastasis (OR = 0.36, 95% CI: 0.22–0.60, p < 0.0001) and tumor stage (OR = 0.43, 95% CI: 0.31–0.60, p < 0.00001). In conclusion, the pooled results in our current work suggest that XIST is an important prognostic biomarker in cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23744